Introduction
a-Synuclein (a-syn) is a protein assumed to play a role in the presynaptic modulation of cell vesicle trafficking [1, 2] . In particular, a-syn binds to specific presynaptic proteins directly involved in the release of neurotransmitters and preserves the synaptic terminals, both at structural and at functional level (Wong and Krainc [1] ; Fang et al., [2] ). Hyperphosphorylated misfolded a-syn proteins, deposited in the brain as insoluble fibrillary aggregates, generate neuronal cytoplasmic inclusions, namely Lewy bodies (LBs) [3] which are pathophysiological hallmarks of several brain proteinopathies with neurodegeneration-including Parkinson disease (PD), PD with dementia, and dementia with Lewy bodies-and oligodendroglial cytoplasmic inclusions-typically found in multiple system atrophy, all belonging to the synucleinopathy spectrum [4, 5] . However, Lewy body pathology is also found in most cases with familial Alzheimer's disease (AD) harboring presenilin (PSEN 1 and 2) mutations [6] .
Hence, a-syn concentrations have been assessed in cerebrospinal fluid (CSF), especially as potential surrogate of cerebral LB deposition, to discriminate in vivo among healthy controls (HCs), PD, and atypical parkinsonian syndromes [7] [8] [9] [10] [11] . In summary, most studies show a minor reduction in CSF total a-syn in PD and LBD.
Moreover, the cellular localization and function of a-syn suggest a potential role as surrogate biomarker of synaptic loss also in non-synucleinopathy neurodegenerative diseases (NDs), such as AD. However, despite numerous research efforts, a general consensus on the relevance of this biomarker candidate in the diagnostic/prognostic workflow of ND is still under debate [12, 13] .
Several studies reported higher CSF a-syn concentrations in patients with AD versus both individuals suffering from other NDs and HCs. However, these results are conflicting, probably due to substantial intersite methodological differences [12] [13] [14] [15] . These include different pre-intra-analytical procedures and assays, performed for CSF a-syn assessment, and different recruitment criteria. Previous studies exploring CSF a-syn concentrations in AD were performed in dementia patients or subjects with prodromal (mild cognitive impairment) forms of the disease [12] [13] [14] .
To the best of our knowledge, no studies examined the potential pathophysiological role of CSF a-syn in the asymptomatic preclinical phase of AD [16] .
Individuals with subjective complaints of memory dysfunction (SMC), together with evidence of cerebral deposition of amyloid b (Ab), are considered asymptomatic individuals at risk of developing AD [16] . Hence, the aim of the study was to cross-sectionally investigate the variations of CSF a-syn concentrations in relation to the pathophysiological mechanisms of AD in a subset of a preclinical cohort.
Materials and methods

Study participants
This research is designed as a monocenter, crosssectional study in a subset of 36 participants with SMC recruited from the "INveStIGation of AlzHeimer's PredicTors in Subjective Memory Complainers" (INSIGHT-preAD) study, a French monocentric academic university-based cohort which is part of the Alzheimer Precision Medicine Initiative Cohort Program [17] . Participants were enrolled at the Institute of Memory and AD (Institut de la M emoire et de la Maladie d'Alzheimer, IM2A) at the Piti e-Salpêtri ere University Hospital in Paris, France. The main goal of the INSIGHT-preAD study is to investigate the earliest preclinical stages of AD and its development, including influencing factors and biomarkers of progression.
The INSIGHT-preAD study includes 318 cognitively normal Caucasian individuals, recruited from the community in the wider Paris area, France, aged 70 to 85 years, with SMC. The status of SMC is confirmed as follows: (1) participants gave an affirmative answer ("yes") to both questions: "Are you complaining about your memory?" and "Is it a regular complaint that has lasted now more than 6 months?"; (2) participants presented intact cognitive functions based on Mini-Mental State Examination score ( 27) , Clinical Dementia Rating scale 5 0, and Free and Cued Selective Rating Test (total recall score 41).
b-Amyloid positron emission tomography (Ab-PET)
investigation is performed at baseline visit, as mandatory study inclusion criterion. Thus, all subjects enrolled into the study have SMC and are stratified as either positive or negative for cerebral Ab deposition.
Briefly, exclusion criteria are represented by the absence of history of neurological or psychiatric diseases.
At the point of study inclusion, several data, such as demographic data and apolipoprotein E genotype (APOE), are collected.
The study was conducted in accordance with the tenets of the Declaration of Helsinki of 1975 and approved by the local institutional review board at the participating center. All participants or their representatives gave written informed consent for the use of their clinical data for research purposes.
For the present study, we included 36 subjects that volunteered for the lumbar puncture at baseline. It has been previously reported that CSF Ab and Ab-PET have comparable diagnostic performance in detecting cerebral Ab deposition, at preclinical or prodromal stages of AD [18] . Thus, CSF Ab was not included in our analyses due to its high degree of intercorrelation with PET data.
CSF sampling
A lumbar puncture was performed at baseline in all 36 participants of the cohort subset. All CSF samples included were collected in polypropylene tubes and centrifuged at 1000 g for 10 min at 4 C. The collected supernatant was aliquoted and stored at -80 C pending biochemical analysis. [19] [20] [21] . All CSF analyses were performed by board-certified laboratory technicians blinded to clinical information.
Immunoassay for CSF a-syn
All CSF a-syn analyses were performed at the Clinical Neurochemistry Laboratory at the Sahlgrenska University Hospital, M€ olndal, Sweden. CSF a-syn protein concentration was measured using the U-PLEX Human a-syn Singleplex immunoassay kit (Meso Scale Discovery, Rockville, MD, US), according to the manufacturer's instructions (available at https://www.mesoscale.com/en/ products/u-plex-human-alpha-synuclein-kit-k151wkk/). The assay consists of a rabbit monoclonal capture antibody coupled with a mouse monoclonal antibody for detection. The lower limit of quantification was 84 pg/mL. All CSF analyses were performed on one occasion with randomized samples using one batch of reagents by board-certified laboratory technicians blinded to clinical information to avoid bias.
PET acquisition
All florbetapir-PET scans are acquired in a single session on a Philips Gemini GXL computed tomography-PET scanner 50 (65) minutes after injection of approximately 370 MBq (333-407 MBq) of florbetapir. PET acquisition consists of 3 ! 5 minutes frames, a 128 ! 128 acquisition matrix and a voxel size of 2 ! 2 ! 2 mm 3 . Images are then reconstructed using iterative LOR-RAMLA algorithm (10 iterations), with a smooth postreconstruction filter. All corrections (attenuation, scatter, and random coincidence) are integrated in the reconstruction. Finally, frames are realigned, averaged, and quality-checked by the Centre pour l'Acquisition et le Traitement des Images (CATI) team. CATI is a French neuroimaging platform funded by the French Plan Alzheimer (available at http://cati-neuroimaging.com).
PET data processing
Reconstructed PET images are analyzed with a pipeline developed by CATI. A standard uptake value ratio (SUVR) with a threshold of 0.7918 has been used to categorize our population as Ab positive or Ab negative according to a method previously described [22] .
Statistical analysis
Demographic characteristics, baseline CSF and imaging characteristics, and scores on neurocognitive tests of the analyzed participants are provided in Table 1 . Continuous variables were described by the median and interquartile ranges.
Differences between the Ab PET-positive and -negative groups in terms of CSF concentrations of core feasible biomarkers and a-syn were explored assuming nonnormal distribution. Thus, a Wilcoxon-Mann-Whitney pairwise comparison test was performed.
We then performed regression analysis preceded by logarithmic transformation of all biomarkers to approximate assumptions of normality and hence remain within the assumptions of linear regression. Associations between log-transformed CSF biomarker concentrations and log-transformed Ab-PET global SUVR values were tested with a series of univariate linear regressions (see Table 2 ). They were conducted to determine the influence of tau (both total and phosphorylated), Ab-PET global SUVR on a-syn values including age and sex as covariates.
To follow and to establish the independent contribution of each biomarker to the prediction of group, a multivariate analysis was carried out (with bootstrapped P values included in Table 3 ). Model 3a approximated a-syn with t-tau 1 SUVR 1 covariates; model 3b, a-syn with ptau 181 1 SUVR covariates (see Table 3 ). Finally, a binary logistic regression was executed setting the PET status as the outcome variable and CSF t-tau, p-tau 181 , and a-syn as predictive factors (see Table 4 ).
All tests performed were two tailed and with a significance set at P , .05.
All statistics are performed using R, v. 3.2.3 (The R Foundation for Statistical Computing).
Results
Comparisons between groups according to the PET status
The median (range) age was 76 (72.5-77) years, and the sex ratio was well balanced (18:18) in the whole subset (see Table 1 ). Subjects were dichotomized according to the Ab-PET status, either positive (N 5 8) or negative (N 5 28), which was identified as the primary outcome. Demographic and clinical data of subjects are shown in Table 1 . Hence, we performed comparisons between the two groups. Notably, Ab-PET positive participants scored an educational level higher than those with negative Ab-PET (see Table 1 ). A significant difference was also found when comparing the two groups for sex ratio (see Table 1 ). NOTE. Logarithmic transformation of CSF variables was used to reduce the skewness of distribution. P value: significant level P , .05, two tailed. The * symbol refers to the presence of statistical significance. Each model is adjusted for age and sex.
CSF concentrations of p-tau 181 and t-tau were significantly different between positive and negative Ab-PET individuals, with the former showing increased concentrations of both p-tau 181 and t-tau (P 5 .003 and P 5 .005, respectively) (see Table 1 ).
A trend but not a significant difference in terms of CSF a-syn concentrations was found between Ab PET-positive and Ab PET-negative subjects (data not shown).
Univariate linear regression analysis of CSF a-syn predictive factors
The univariate linear regression models including age and sex as covariates showed that CSF t-tau, CSF p-tau 181 Table 2 and Fig. 1 ).
Multivariate linear regression analysis of CSF a-syn predictive factors
The multivariate linear regression model, including both global SUVR and CSF t-tau, showed that an increase of one unit of CSF t-tau concentration resulted in a significant increase of 0.71 (0.08) pg/mL (P ,.001) in CSF a-syn concentration, after adjusting for age and sex. This model is accurate with an adjusted R-squared value of 0.80 (for more details, see Table 3 ).
At a lesser extent, a similar arrangement, including global SUVR and CSF p-tau 181 instead of CSF t-tau, resulted into a model in which an increase of one unit of CSF p-tau 181 concentration lead to a significant increase of 0.48 (0.12) pg/mL (P , .01) in CSF a-syn concentration, after adjusting for age and sex (see Table 3 ).
We decided not to include CSF p-tau 181 and CSF t-tau together in the same model given the existence of a high degree of collinearity between the two variables, which notoriously makes model estimation unstable (data not shown).
Logistic regression analysis for PET status
The regression for CSF a-syn was significant with a positive odds ratio, indicating that greater values of the marker are more likely to explain an increased cerebral Ab load. The same was found for t-tau and p-tau 181 (see Table 4 ).
Discussion
Using a cross-sectional study design in a large monocentric cohort (INSIGHT-preAD)-within the framework of the Alzheimer Precision Medicine Initiative as part of the Alzheimer Precision Medicine Initiative Cohort Program-we found a positive association between CSF a-syn concentrations and mean cortical SUVR in asymptomatic subjects at risk of AD. This association was confirmed using multivariate analysis after adjusting for age and sex. Emerging evidences from pathological studies suggest that about 10%-40% of patients with AD showed concomitant brain LB deposition [23] [24] [25] . In addition, cerebral Ab pathology is a common finding in synucleinopathies, especially in dementia with Lewy bodies individuals [26, 27] . Abbreviations: CSF, cerebrospinal fluid; PET, positron emission tomography; t-tau, total tau; p-tau 181 , hyperphosphorylated tau at Threonine site 181; SUVR, mean standardized uptake value ratio; Log, logarithmic transformation.
NOTE. Log transformation of CSF variables was used to reduce the skewness of distribution. P value: significant level P , .05, two tailed. The * symbol refers to the presence of statistical significance. The model is adjusted for age and sex. .002* Abbreviations: a-syn, a-synuclein; CSF, cerebrospinal fluid; PET, positron emission tomography; t-tau, total tau; p-tau 181 , hyperphosphorylated tau at Threonine site 181; Log: logarithmic transformation.
NOTE. Logarithmic transformation of CSF variables was used to reduce the skewness of distribution.
P value: significant level P , .05, two tailed. The * symbol refers to the presence of statistical significance. The model is adjusted for age and sex.
Recently, the existence of an anti-Ab deposition effect of a-syn has been proposed in a mouse model of AD [28] . This observation, if confirmed in humans, might provide novel insights into potential targets for precise pathomechanistic therapies of AD and synucleinopathies.
Although we found a trend of increased CSF a-syn concentrations in Ab PET-positive compared with Ab PETnegative subjects, these values did not reach statistical significance likely due to the relatively small sample size. Previous studies also explored the diagnostic value of CSF a-syn concentrations-alone or in combination with the CSF core feasible biomarkers Ab 1-42 , t-tau, and p-tau 181 -differentiating a large spectrum of ND, including AD [12] [13] [14] [15] . Although some results are still controversial, most studies reported increased CSF a-syn concentrations in AD compared with other ND and HC [12, 13] . Discrepancies emerging from these data might be attributable to a high degree of intersite variability and to analytical and methodological differences, such as the CSF measurement of either the full-size protein or specific oligomers of a-syn [8, 12, 13] . Furthermore, most of the investigations lack of a reliable HC group [8, 12, 13] .
Furthermore, we disclosed a positive association between CSF a-syn and CSF t-tau and p-tau 181 , using both univariate and multivariate analyses. This finding is consistent with those emerging from investigations performed in mouse models and in humans. In general, the brain extracellular increase of both tau and a-syn concentrations is related to the concomitant neuronal loss and the increased level of phosphorylation preceding the aggregation process, leading to LB and neurofibrillary tangles, respectively [1] . Indeed, hyperphosphorylation is a posttranslational modification common to several misfolded proteins accumulating in the brain, including a-syn [29, 30] . In particular, phosphorylation at S129 (pS129) is the most common alteration characterizing this protein in its fibrillar aggregates. Interestingly, the increase of both CSF a-syn and tau protein concentrations might be considered an early biomarker reflecting different pathophysiological mechanisms leading to neurodegeneration, in particular synaptic degeneration and neuronal death, respectively. In this regard, CSF a-syn concentrations in AD are also tightly associated with other neurodegeneration surrogates such as gray matter atrophy and cerebral hypometabolism, measured using magnetic resonance imaging and 18 F-2-fluoro-2-deoxy-D-glucose PET [12] [13] [14] [15] . Notably, since a-syn is involved in glutamatergic neuronal transmission, the hippocampal atrophy, an early feature of AD pathophysiology, might explain the increased concentrations of CSF a-syn in patients with AD [1, 4, 31, 32] . Finally, a possible synergistic link between a-syn and tau protein byproducts on neurodegeneration has been suggested [33, 34] . Such an interaction is supposed to facilitate the spreading of LB and the deposition of neurofibrillary tangles activated by an imbalance between brain kinases and phosphatases [1, 29, 34] .
This study presents some caveats. First, the sample size is relatively limited thus hindering any CSF core biomarkerbased stratification of our individuals. Second, due to small sample size, we did not include APOE genotype and education level as additional covariates, preventing the opportunity to exclude that the associations found in this study were partially driven by differences in APOE and education between the high and low amyloid subgroups.
Third, given that this is a cross-sectional study and longitudinal data are not yet available, it is not possible to state whether increased CSF a-syn concentrations predict the onset of AD or other ND, such as, dementia with Lewy bodies. Moreover, structural magnetic resonance imaging analyses, which are useful to confirm the presence of direct cerebral evidences of neurodegeneration, were not reported. Fig. 1 . Plots showing the association between CSF a-synuclein and global SUVR, CSF a-synuclein and CSF t-tau, and CSF a-synuclein and CSF p-tau 181 : the univariate analysis. Notes. For each curve, b slope and standard deviation (SD) are indicated with respective P value (significant level P , .05) adjusted for age and sex. Abbreviations: CSF, cerebrospinal fluid; p-tau, hyperphosphorylated tau at Threonine site 181; t-tau, total tau; SUVR, standard uptake value ratios; Log, logarithmic transformation.
In summary, we found that increased CSF a-syn concentrations are potentially associated with early AD pathophysiology-in terms of both amyloid-and tau-related pathophysiological mechanisms-during the asymptomatic stage of the disease. Longitudinal studies with larger sample size are needed to assess whether increased concentrations of CSF a-syn could represent a predictive surrogate outcome of cognitive impairment and neurodegeneration in asymptomatic at risk of AD subjects. This in turn will allow depicting different longitudinal molecular trajectories underpinning apparently similar phenotypes.
In conclusion, if our results will be confirmed in larger samples, we believe that CSF a-syn could represent an additional molecular candidate biomarker to be integrated in the expanding biomarker array needed to accurately stratify cohorts (biomarker-guided) of individuals at risk of AD or other ND according to distinctive pathophysiological pathways. From a translational perspective, this enhanced biomarker guidance is expected to substantially optimize the basis to develop and enhance effective targeted therapeutic strategies for the efficient treatment of the individual subject, in line with the evolving precision medicine paradigm [17, [35] [36] [37] . Supplementary investigations will be essential to address the open issues which the present study cannot address due to methodological limit as the total and the Ab PET-positive sample size. Throughout removing these potential biases, it will possible to establish whether CSF a-syn may be utilized as a biological indicator of mechanism of action and/or target engagement or even as a biological marker to predict the progression of cognitive decline in drug development analyses. Indeed, increasingly accurate guideposts are necessary both to identify the disease at its earliest preclinical stages and to commence treatment strategies of specific pathophysiological mechanisms via biomarker-guided targeted therapy trials.
RESEARCH IN CONTEXT
1. Systematic review: Previous studies investigating cerebrospinal fluid (CSF) a-synuclein (a-syn) concentrations in Alzheimer's disease are conflicting, probably due to substantial intersite methodological differences. These include different pre-intraanalytical procedures and assays, performed for CSF a-syn assessment, and different recruitment criteria.
To the best of our knowledge, no studies examined the potential pathophysiological role of CSF a-syn in the asymptomatic preclinical phase of Alzheimer's disease. We performed a cross-sectional study in a large-scale monocentric preclinical at risk cohort (INSIGHTpreAD).
Interpretation:
We disclosed a positive association between CSF a-syn concentrations and brain b-amyloid deposition in terms of positron emission tomography standard uptake value ratios. There were also positive correlations between CSF a-syn and both CSF t-tau and p-tau 181 concentrations.
3. Future directions: It has previously been shown that a-syn may synergistically and directly induce posttranslational modifications of both tau and b-amyloid. Therefore, the main findings of this study indicate an association of CSF a-syn with Alzheimer's disease-related pathophysiological mechanisms, during the preclinical phase of the disease.
